Hypoxia-Mimicking Nanofibrous Scaffolds Promote Endogenous Bone Regeneration

Qingqing Yao, Yangxi Liu, Jianning Tao, Keith M. Baumgarten, Hongli Sun

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Utilizing biomimetic materials to potentiate endogenous cell growth or signaling is superior to relying on exogenous cells or signals for bone formation. Desferoxamine (DFO), which is a hypoxia-mimetic agent that chelates iron (Fe3+), mimics hypoxia to encourage bone healing. However, high cytotoxicity, off-target effects, and the short half-life of DFO have significantly impeded its further applications. We mitigated these side effects by locally immobilizing DFO onto a gelatin nanofibrous (GF) scaffold that retained DFO's ability to chelate Fe3+. Moreover, DFO-functionalized GF (GF-DFO) scaffolds, which have similar micro/macrostructures to GF scaffolds, not only demonstrated decreased cytotoxicity on both human umbilical vein endothelial cells and human mesenchymal stem cells but also significantly increased vascular endothelial growth factor (VEGF) expression in vitro. Most importantly, in our in vivo experiments on a critical-sized cranial bone defect mouse model, a significant amount of bone was formed in most of the GF-DFO scaffolds after six weeks, while very little new bone was observed in the GF scaffolds. These data suggest that use of a hypoxia-mimicking nanofibrous scaffold is a promising strategy for promoting endogenous bone formation.

Original languageEnglish (US)
Pages (from-to)32450-32459
Number of pages10
JournalACS Applied Materials and Interfaces
Volume8
Issue number47
DOIs
StatePublished - Nov 30 2016
Externally publishedYes

Fingerprint

Scaffolds
Bone
Cytotoxicity
Biomimetic materials
Iron Chelating Agents
Cell signaling
Endothelial cells
Cell growth
Gelatin
Scaffolds (biology)
Stem cells
Vascular Endothelial Growth Factor A
Iron
Defects
Experiments

Keywords

  • angiogenesis
  • desferoxamine
  • endogenous bone regeneration
  • hypoxia
  • nanofibrous scaffold

ASJC Scopus subject areas

  • Materials Science(all)

Cite this

Hypoxia-Mimicking Nanofibrous Scaffolds Promote Endogenous Bone Regeneration. / Yao, Qingqing; Liu, Yangxi; Tao, Jianning; Baumgarten, Keith M.; Sun, Hongli.

In: ACS Applied Materials and Interfaces, Vol. 8, No. 47, 30.11.2016, p. 32450-32459.

Research output: Contribution to journalArticle

Yao, Qingqing ; Liu, Yangxi ; Tao, Jianning ; Baumgarten, Keith M. ; Sun, Hongli. / Hypoxia-Mimicking Nanofibrous Scaffolds Promote Endogenous Bone Regeneration. In: ACS Applied Materials and Interfaces. 2016 ; Vol. 8, No. 47. pp. 32450-32459.
@article{0ecb54ce5d3a4bf8bc2a90eb84c29e6e,
title = "Hypoxia-Mimicking Nanofibrous Scaffolds Promote Endogenous Bone Regeneration",
abstract = "Utilizing biomimetic materials to potentiate endogenous cell growth or signaling is superior to relying on exogenous cells or signals for bone formation. Desferoxamine (DFO), which is a hypoxia-mimetic agent that chelates iron (Fe3+), mimics hypoxia to encourage bone healing. However, high cytotoxicity, off-target effects, and the short half-life of DFO have significantly impeded its further applications. We mitigated these side effects by locally immobilizing DFO onto a gelatin nanofibrous (GF) scaffold that retained DFO's ability to chelate Fe3+. Moreover, DFO-functionalized GF (GF-DFO) scaffolds, which have similar micro/macrostructures to GF scaffolds, not only demonstrated decreased cytotoxicity on both human umbilical vein endothelial cells and human mesenchymal stem cells but also significantly increased vascular endothelial growth factor (VEGF) expression in vitro. Most importantly, in our in vivo experiments on a critical-sized cranial bone defect mouse model, a significant amount of bone was formed in most of the GF-DFO scaffolds after six weeks, while very little new bone was observed in the GF scaffolds. These data suggest that use of a hypoxia-mimicking nanofibrous scaffold is a promising strategy for promoting endogenous bone formation.",
keywords = "angiogenesis, desferoxamine, endogenous bone regeneration, hypoxia, nanofibrous scaffold",
author = "Qingqing Yao and Yangxi Liu and Jianning Tao and Baumgarten, {Keith M.} and Hongli Sun",
year = "2016",
month = "11",
day = "30",
doi = "10.1021/acsami.6b10538",
language = "English (US)",
volume = "8",
pages = "32450--32459",
journal = "ACS applied materials & interfaces",
issn = "1944-8244",
publisher = "American Chemical Society",
number = "47",

}

TY - JOUR

T1 - Hypoxia-Mimicking Nanofibrous Scaffolds Promote Endogenous Bone Regeneration

AU - Yao, Qingqing

AU - Liu, Yangxi

AU - Tao, Jianning

AU - Baumgarten, Keith M.

AU - Sun, Hongli

PY - 2016/11/30

Y1 - 2016/11/30

N2 - Utilizing biomimetic materials to potentiate endogenous cell growth or signaling is superior to relying on exogenous cells or signals for bone formation. Desferoxamine (DFO), which is a hypoxia-mimetic agent that chelates iron (Fe3+), mimics hypoxia to encourage bone healing. However, high cytotoxicity, off-target effects, and the short half-life of DFO have significantly impeded its further applications. We mitigated these side effects by locally immobilizing DFO onto a gelatin nanofibrous (GF) scaffold that retained DFO's ability to chelate Fe3+. Moreover, DFO-functionalized GF (GF-DFO) scaffolds, which have similar micro/macrostructures to GF scaffolds, not only demonstrated decreased cytotoxicity on both human umbilical vein endothelial cells and human mesenchymal stem cells but also significantly increased vascular endothelial growth factor (VEGF) expression in vitro. Most importantly, in our in vivo experiments on a critical-sized cranial bone defect mouse model, a significant amount of bone was formed in most of the GF-DFO scaffolds after six weeks, while very little new bone was observed in the GF scaffolds. These data suggest that use of a hypoxia-mimicking nanofibrous scaffold is a promising strategy for promoting endogenous bone formation.

AB - Utilizing biomimetic materials to potentiate endogenous cell growth or signaling is superior to relying on exogenous cells or signals for bone formation. Desferoxamine (DFO), which is a hypoxia-mimetic agent that chelates iron (Fe3+), mimics hypoxia to encourage bone healing. However, high cytotoxicity, off-target effects, and the short half-life of DFO have significantly impeded its further applications. We mitigated these side effects by locally immobilizing DFO onto a gelatin nanofibrous (GF) scaffold that retained DFO's ability to chelate Fe3+. Moreover, DFO-functionalized GF (GF-DFO) scaffolds, which have similar micro/macrostructures to GF scaffolds, not only demonstrated decreased cytotoxicity on both human umbilical vein endothelial cells and human mesenchymal stem cells but also significantly increased vascular endothelial growth factor (VEGF) expression in vitro. Most importantly, in our in vivo experiments on a critical-sized cranial bone defect mouse model, a significant amount of bone was formed in most of the GF-DFO scaffolds after six weeks, while very little new bone was observed in the GF scaffolds. These data suggest that use of a hypoxia-mimicking nanofibrous scaffold is a promising strategy for promoting endogenous bone formation.

KW - angiogenesis

KW - desferoxamine

KW - endogenous bone regeneration

KW - hypoxia

KW - nanofibrous scaffold

UR - http://www.scopus.com/inward/record.url?scp=84999792327&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84999792327&partnerID=8YFLogxK

U2 - 10.1021/acsami.6b10538

DO - 10.1021/acsami.6b10538

M3 - Article

VL - 8

SP - 32450

EP - 32459

JO - ACS applied materials & interfaces

JF - ACS applied materials & interfaces

SN - 1944-8244

IS - 47

ER -